EGFR and lung adenocarcinoma: The understanding of the molecular bases of lung cancer with the discovery of driver mutations, such as in epidermal growth factor receptor (EGFR) gene in lung adenocarcinoma [3], and the identification of immune checkpoints that regulate the tumor immune response [4] have allowed the development of new therapies.